{{Rsnum
|rsid=12762549
|Chromosome=10
|position=101620771
|Orientation=plus
|GMAF=0.4848
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 36.6 | 41.1 | 22.3
| HCB | 15.3 | 49.6 | 35.0
| JPT | 18.6 | 49.6 | 31.9
| YRI | 39.5 | 49.7 | 10.9
| ASW | 38.6 | 40.4 | 21.1
| CHB | 15.3 | 49.6 | 35.0
| CHD | 19.6 | 47.7 | 32.7
| GIH | 18.0 | 52.0 | 30.0
| LWK | 26.4 | 56.4 | 17.3
| MEX | 13.8 | 58.6 | 27.6
| MKK | 30.1 | 50.0 | 19.9
| TSI | 22.0 | 53.0 | 25.0
| HapMapRevision=28
}}{{PMID|18294295}} [[rs12762549]] and [[rs11045585]] can be used to predict whether [[docetaxel]] will induced leukopenia/neutropenia, according to a study of ~100 Japanese patients. When patients were classified into three groups by the scoring system based on the genotypes of these two SNPs, patients with a score of 1 or 2 were shown to have a significantly higher risk of docetaxel-induced leukopenia/neutropenia as compared to those with a score of 0 (P = 0.0000057; odds ratio [OR], 7.00; 95% CI [confidence interval], 2.95-16.59). This prediction system correctly classified 69.2% of severe leukopenia/neutropenia and 75.7% of non-leukopenia/neutropenia into the respective categories.

{{PharmGKB
|RSID=rs12762549
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:18294295
|Annotation=In a case control study using samples from BioBank Japan, the G allele of rs12762549 was associated with docetaxel-induced leukopenia/neutropenia.
|Drugs=docetaxel
|Drug Classes=
|Diseases=Leukopenia; Neutropenia
|Curation Level=Curated
|PharmGKB Accession ID=PA162316676
}}

{{PharmGKB
|RSID=rs12762549
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:18294295
|Annotation=A case-control association study in 84 patients who received docetaxel chemotherapy found a significant association of rs12762549 in ABCC2 with docetaxel-induced leukopenia/neutropenia.
|Drugs=docetaxel
|Drug Classes=
|Diseases=Leukopenia; Neutropenia
|Curation Level=Curated
|PharmGKB Accession ID=PA162191294
}}

{{PMID Auto
|PMID=22407408
|Title=Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12762549
|overall_frequency_n=65
|overall_frequency_d=128
|overall_frequency=0.507812
|n_genomes=43
|n_genomes_annotated=0
|n_haplomes=56
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}